Latest Updates

9/18/2014 - Management of HCV Infection
  • Updated with new approval of daclatasvir by the European Commission

5/8/2014 - HCV Management in Special Populations

4/18/2014 - HBV in Special Populations

4/1/2014 - Management of HCV Infection

2/25/2014 - Management of HCV Infection
  • Summary of the American Association for the Study of Liver Diseases and Infectious Diseases Society of America 2014 guideline recommendations on treatment of chronic hepatitis C
  • Summary of the European Association for the Study of the Liver 2013 guideline recommendations on treatment of chronic hepatitis C
  • EMEA approval of sofosbuvir for patients infected with chronic genotype 1-6 HCV

1/15/2014 - HBV Epidemiology

1/8/2014 - Management of HCV Infection
  • Updated briefly to acknowledge US FDA approval of simeprevir and sofosbuvir for treatment of HCV 

12/2/2013 - Management of HCV Infection
  • Updated to reflect US FDA approval of twice-daily dosing of telaprevir 

10/24/2013 - Management of HCV Infection
  • Video Insight: Updated to include a video commentary in which Eric Lawitz, MD, CPI, summarizes key data from the phase III trials of sofosbuvir, simeprevir, and faldaprevir presented at the 2013 EASL and DDW meetings

8/19/2013 - Management of HCV Infection
  • Updated to reflect the approval of eltrombopag to treat thrombocytopenia in order to allow initiation or maintenance of peginterferon-based HCV therapy
  • Updated to include discussion of the use of transient elastography, newly approved by the FDA, in the evaluation of liver disease severity
  • Added discussion of twice-daily dosing of telaprevir, which has been approved for use by the European Commission

7/31/2013 - Management of HCV Infection
  • Journal Highlight: Improved SVR12 rates with sofosbuvir/ribavirin in genotype 2/3 HCV–infected patients ineligible for or intolerant of interferon-based regimens in the POSITRON and FUSION studies.

7/26/2013 - Other Viruses

6/5/2013 - Management of HCV Infection
  • Journal Highlight: SVR associated with reductions in all-cause mortality as well as liver-related mortality or liver transplantation, hepatocellular carcinoma, and liver failure.

1/22/2013 - Management of HCV Infection
  • Video Insight: Updated to include a video commentary in which Marc Bourlière, MD, and Nezam H. Afdhal, MD, FRCPI, discuss new findings from the CUPIC study and the impact of these findings on patient care
  • New data from the CUPIC study, including predictors of severe complications and the need for transfusion
  • New data on management of anemia during protease inhibitor–based therapy

11/9/2012 - Management of HCV Infection
  • A new section on which patients with chronic hepatitis C should be treated with currently available regimens and which patients may benefit from waiting for newer therapies 
  • Updated data on the use of boceprevir in patients with previous null response to peginterferon/ribavirin
  • Updated findings and a new section the use of boceprevir- or telaprevir-based triple therapy in patients with cirrhosis
  • New data on the value of detectable but unquantifiable HCV RNA vs undetectable HCV RNA at key on-treatment time points for response-guided therapy with protease inhibitor–based triple therapy
  • Updated guidance on drug–drug interactions with boceprevir and telaprevir
  • New data regarding the impact of baseline insulin resistance on response to telaprevir-based triple therapy
  • Updated findings on the value of futility rules during telaprevir-based triple therapy
  • New data on the optimal management of anemia in patients receiving boceprevir- or telaprevir-based triple therapy
  • Journal Highlight: New data on the use of oral silymarin for treatment of HCV among individuals who failed treatment with interferon-based therapy

12/13/2011 - Management of HCV Infection
  • Now available: In this module, Jordan J. Feld, MD, MPH, and Hemant Shah, MD, FRCPC, review optimal strategies for managing patients with hepatitis C virus infection.